Starting 2027-01-01, UnitedHealthcare Community Plan of Tennessee revised its Saphnelo (anifrolumab-fnia) IV medical policy for moderate to severe systemic lupus erythematosus. Initial and continuation requests now require a prescriber attestation, with explanation, that the patient or caregiver cannot be trained or is physically unable to self-administer Saphnelo or Benlysta, along with a history of failure, contraindication, or intolerance to Benlysta IV or SQ for initial therapy. Saphnelo pen for self-administered subcutaneous injection falls under the pharmacy benefit rather than this policy.
Get alerts when payers change rules like this one
We check UnitedHealthcare and other payers every day and email you when a change matches your specialty and state.
01By 2027-01-01: Billing team and providers should confirm that Saphnelo IV requests and claims for Tennessee Medicaid members with UnitedHealthcare Community Plan include the prescriber attestation on self-administration ability and a written explanation, plus documented Benlysta IV or SQ history for initial therapy.
02Update the prior auth tracker and intake checklist accordingly.
03Confirm that Saphnelo pen prescriptions for self-administration are routed to pharmacy benefit processing, and tell providers and front desk staff about the rheumatologist-prescriber, concurrent-biologic, dosing, and 12-month authorization limit requirements.
04Claims without the required prior authorization documentation will be denied.
Original notice
Saphnelo® (Anifrolumab-Fnia)
uhcprovider.com · Always check the source before changing claims.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.